CytoSorbents to Report Q1 2020 Operating and Financial Results

CytoSorbents to Report Q1 2020 Operating

and Financial Results

MONMOUTH JUNCTION, N.J., April 28, 2020 /PRNewswire/ -

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification

technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q1 2020

financial results after the market close on Tuesday, May 5, 2020.

CytoSorbents' management will host a live conference call

and presentation webcast that will recount both operational and financial progress during Q1 2020 followed by a question and answer

It is recommended that participants dial in approximately 10

minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be

accessed through the following audio feed link: http://public.viavid.com/index.php?id=139054

An archived recording of the conference call will be available

under the Investor Relations section of the Company's website at http://cytosorbents.com/investor-relations/financial-results/

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical

care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb is approved in the European

Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine

storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death

in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist.

CytoSorb has been used in more than 80,000 human treatments to date. CytoSorb has received FDA Emergency Use Authorization

in the United States for use in critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined

circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary

bypass circuit during emergent and urgent cardiothoracic surgery.

CytoSorbents' purification technologies are based on

biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore

capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of nearly $29 million from

DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart,

Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), the U.S. Army, U.S. Special Operations Command

(USSOCOM), the U.S. Air Force, Air Force Material Command (USAF/AFMC) and others. The Company has numerous products under development

based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications

pending, including CytoSorb-XL , HemoDefend , VetResQ , K+ontrol , ContrastSorb, DrugSorb,

and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com

Forward-Looking Statements

This press release includes forward-looking statements intended

to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking

statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not

historical facts and typically are identified by use of terms such as "may," "should," "could,"

"expect," "plan," "anticipate," "believe," "estimate," "predict,"

"potential," "continue" and similar words, although some forward-looking statements are expressed differently.

You should be aware that the forward-looking statements in this press release represent management's current judgment and

expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements.

Factors which could cause or contribute to such differences include, but are not limited to, our ability to leverage designation

of CytoSorb as a breakthrough device under the FDA's Breakthrough Devices Program in order to expedite the development,

assessment, and regulatory review of CytoSorb, as well as the risks discussed in our Annual Report on Form 10-K, filed with the

SEC on March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and Current Reports on Form

8-K, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise

interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any

such forward-looking statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by

rapidly changing state and federal regulations, as well as the health and availability of their workforce. We undertake no obligation

to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise,

other than as required under the Federal securities laws.

CytoSorbents Contact:

Investor Relations Contact:

Public Relations Contact:

Rubenstein Public Relations

SOURCE CytoSorbents Corporation